{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T22:22:22Z","timestamp":1768083742640,"version":"3.49.0"},"publisher-location":"Boston, MA","reference-count":55,"publisher":"Springer US","isbn-type":[{"value":"9781441902832","type":"print"},{"value":"9781441902849","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009]]},"DOI":"10.1007\/978-1-4419-0284-9_27","type":"book-chapter","created":{"date-parts":[[2010,3,2]],"date-time":"2010-03-02T15:41:26Z","timestamp":1267544486000},"page":"467-478","source":"Crossref","is-referenced-by-count":93,"title":["Current Concepts on the Molecular Biology of Osteosarcoma"],"prefix":"10.1007","author":[{"given":"Richard","family":"Gorlick","sequence":"first","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2009,8,12]]},"reference":[{"key":"27_CR1_27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V","volume":"75","author":"HD Dorfman","year":"1995","unstructured":"Dorfman HD, Czerniak B. Bone cancers. Cancer. 1995;75:203-210.","journal-title":"Cancer"},{"key":"27_CR2_27","volume-title":"Bone Tumors: Diagnosis, Treatment and Prognosis","author":"A Huvos","year":"1991","unstructured":"Huvos A. Bone Tumors: Diagnosis, Treatment and Prognosis. 2nd ed. WB Saunders: Philadelphia; 1991.","edition":"2"},{"key":"27_CR3_27","first-page":"2019","volume-title":"Cancer Medicine","author":"R Gorlick","year":"2006","unstructured":"Gorlick R, Bernstein ML, Toretsky JA, et al. Bone Tumours. In: Holland J, Frei E, eds. Cancer Medicine. 7th ed. Hamilton, ON: BC Decker; 2006:2019-2027.","edition":"7"},{"key":"27_CR4_27","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0031-3955(05)70540-X","volume":"44","author":"PA Meyers","year":"1997","unstructured":"Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin N Am. 1997;44:973-989.","journal-title":"Pediatr Clin N Am"},{"key":"27_CR5_27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/15227950050193641","volume":"19","author":"M Ladanyi","year":"2000","unstructured":"Ladanyi M, Gorlick R. The molecular pathology and pharmacology of osteosarcoma. Pediatr Pathol Mol Med. 2000;19:391-413.","journal-title":"Pediatr Pathol Mol Med"},{"key":"27_CR6_27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2407-4-45","volume":"4","author":"T-K Man","year":"2004","unstructured":"Man T-K, Lu X-Y, Jaeweon K, et al. Genome-wide array comparative genomic hybridization reveals distinct amplifications in osteosarcoma. BMC Cancer. 2004;4:45.","journal-title":"BMC Cancer"},{"key":"27_CR7_27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/gcc.10291","volume":"39","author":"CC Lau","year":"2004","unstructured":"Lau CC, Harris CP, Lu X-Y, et al. Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcomas. Genes Chromosomes Cancer. 2004;39:11-21.","journal-title":"Genes Chromosomes Cancer"},{"key":"27_CR8_27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/gcc.10132","volume":"36","author":"J Bayani","year":"2003","unstructured":"Bayani J, Zielenska M, Pandita A, et al. Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes Cancer. 2003;36:7-16.","journal-title":"Genes Chromosomes Cancer"},{"key":"27_CR9_27","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1086\/302019","volume":"63","author":"MJ Nellissery","year":"1998","unstructured":"Nellissery MJ, Padalecki SS, Brkanac Z, et al. Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone. Am J Hum Genet. 1998;63:817-824.","journal-title":"Am J Hum Genet"},{"key":"27_CR10_27","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1001\/jama.278.15.1262","volume":"278","author":"FL Wong","year":"1997","unstructured":"Wong FL, Boice JD, Abramson DH, et al. Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. JAMA. 1997;278:1262-1267.","journal-title":"JAMA"},{"key":"27_CR11_27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/bjc.1986.110","volume":"53","author":"GJ Draper","year":"1986","unstructured":"Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer. 1986;53:661-671.","journal-title":"Br J Cancer"},{"key":"27_CR12_27","first-page":"3042","volume":"54","author":"B Wadayama","year":"1994","unstructured":"Wadayama B, Toguchida J, Shimizu T, et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res. 1994;54:3042-3048.","journal-title":"Cancer Res"},{"key":"27_CR13_27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/(SICI)1097-0215(19991022)84:5<489::AID-IJC7>3.0.CO;2-D","volume":"84","author":"MS Benassi","year":"1999","unstructured":"Benassi MS, Molendini L, Gamberi G, et al. Alteration of pRb\/p16\/cdk4 regulation in human osteosarcoma. Int J Cancer. 1999;84:489-493.","journal-title":"Int J Cancer"},{"key":"27_CR14_27","doi-asserted-by":"publisher","first-page":"6216","DOI":"10.1073\/pnas.82.18.6216","volume":"82","author":"MF Hansen","year":"1985","unstructured":"Hansen MF, Koufos A, Gallie BL, et al. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci U S A. 1985;82:6216-6220.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"27_CR15_27","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1001\/archopht.119.11.1699","volume":"119","author":"JW Harbour","year":"2001","unstructured":"Harbour JW. Molecular basis of low-penetrance retinoblastoma. Arch Ophthalmol. 2001;119:1699-1704.","journal-title":"Arch Ophthalmol"},{"key":"27_CR16_27","first-page":"5358","volume":"48","author":"FP Li","year":"1988","unstructured":"Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48:5358-5362.","journal-title":"Cancer Res"},{"key":"27_CR17_27","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1126\/science.1978757","volume":"250","author":"D Malkin","year":"1990","unstructured":"Malkin D, Li FP, Strong LC, et al. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233-1238.","journal-title":"Science"},{"key":"27_CR18_27","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1541::AID-CNCR15>3.0.CO;2-Y","volume":"79","author":"F Lonardo","year":"1997","unstructured":"Lonardo F, Ueda T, Huvos AG, Healey J, Ladanyi M. p53 and MDM2 alterations in osteosarcomas: Correlation with clinicopathologic features and proliferative rate. Cancer. 1997;79:1541-1547.","journal-title":"Cancer"},{"key":"27_CR19_27","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1994.12.5.925","volume":"12","author":"JF McIntyre","year":"1994","unstructured":"McIntyre JF, Smith-Sorensen B, Friend SH, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol. 1994;12:925-930.","journal-title":"J Clin Oncol"},{"key":"27_CR20_27","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/jnci\/95.9.669","volume":"95","author":"LL Wang","year":"2003","unstructured":"Wang LL, Gannavarapu A, Kozinetz CA, et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund\u2013Thomson syndrome. J Natl Cancer Inst. 2003;95:669-674.","journal-title":"J Natl Cancer Inst"},{"key":"27_CR21_27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ijc.20269","volume":"111","author":"K Nishijo","year":"2004","unstructured":"Nishijo K, Nakayama T, Aoyama T, et al. Mutation analysis of the RECQL4 gene in sporadic osteosarcomas. Int J Cancer. 2004;111:367-372.","journal-title":"Int J Cancer"},{"key":"27_CR22_27","first-page":"239","volume":"5","author":"M Goto","year":"1996","unstructured":"Goto M, Miller RW, Ishikawa Y, Sugano H. Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomarkers Prev. 1996;5:239-246.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"27_CR23_27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0960-9822(00)00002-6","volume":"4","author":"T Jacks","year":"1994","unstructured":"Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994;4:1-7.","journal-title":"Curr Biol"},{"key":"27_CR24_27","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1083\/jcb.122.3.685","volume":"122","author":"AE Grigoriadis","year":"1993","unstructured":"Grigoriadis AE, Schellander K, Wang ZW, Wagner ER. Osteoblasts are target cells for transformation in c-fos transgenic mice. J Cell Biol. 1993;122:685-701.","journal-title":"J Cell Biol"},{"key":"27_CR25_27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1126\/science.1071489","volume":"297","author":"M Jain","year":"2002","unstructured":"Jain M, Arvanitis C, Chu K, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002;297:102-104.","journal-title":"Science"},{"key":"27_CR26_27","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1002\/cncr.22595","volume":"109","author":"T Yan","year":"2007","unstructured":"Yan T, Wunder JS, Gokgoz N, et al. COPS3 amplification and clinical outcome in osteosarcoma. Cancer. 2007;109:1870-1876.","journal-title":"Cancer"},{"key":"27_CR27_27","first-page":"259","volume":"137","author":"BB Knowles","year":"1990","unstructured":"Knowles BB, McCarrick J, Fox N, Solter D, Damjanov I. Osteosarcomas in transgenic mice expressing an alpha-amylase-SV40 T-antigen hybrid gene. Am J Pathol. 1990;137:259-262.","journal-title":"Am J Pathol"},{"key":"27_CR28_27","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/01926230252929882","volume":"30","author":"JL Vahle","year":"2002","unstructured":"Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30:312-321.","journal-title":"Toxicol Pathol"},{"key":"27_CR29_27","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/22780","volume":"400","author":"WC Hahn","year":"1999","unstructured":"Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature. 1999;400:464-468.","journal-title":"Nature"},{"key":"27_CR30_27","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ijc.11487","volume":"107","author":"R Baserga","year":"2003","unstructured":"Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer. 2003;107:873-877.","journal-title":"Int J Cancer"},{"key":"27_CR31_27","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/(SICI)1097-0215(19990209)80:4<581::AID-IJC16>3.0.CO;2-O","volume":"80","author":"S Benini","year":"1999","unstructured":"Benini S, Baldini N, Manara MC, et al. Redundancy of autocrine loops in human osteosarcoma cells. Int J Cancer. 1999;80:581-588.","journal-title":"Int J Cancer"},{"key":"27_CR32_27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/(SICI)1096-9098(199809)69:1<21::AID-JSO5>3.0.CO;2-M","volume":"69","author":"S Burrow","year":"1998","unstructured":"Burrow S, Andrulis IL, Pollak M, Bell RS. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol. 1998;69:21-27.","journal-title":"J Surg Oncol"},{"key":"27_CR33_27","first-page":"739","volume":"10","author":"R Ferracini","year":"1995","unstructured":"Ferracini R, Renzo MFD, Scotlandi K, et al. The Met\/HGF receptor is overexpressed in human osteosarcomas and is activated by either a paracrine or autocrine circuit. Oncogene. 1995;10:739-749.","journal-title":"Oncogene"},{"key":"27_CR34_27","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.1999.17.9.2781","volume":"17","author":"R Gorlick","year":"1999","unstructured":"Gorlick R, Huvos AG, Heller G, et al. Expression of HER2\/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 1999;17:2781-2788.","journal-title":"J Clin Oncol"},{"key":"27_CR35_27","first-page":"572","volume":"6","author":"M Kaya","year":"2000","unstructured":"Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000;6:572-577.","journal-title":"Clin Cancer Res"},{"key":"27_CR36_27","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1158\/0008-5472.CAN-03-3096","volume":"64","author":"DP Hughes","year":"2004","unstructured":"Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. Cell surface expression of epidermal growth factor receptor and her-2 with nuclear expression of her-4 in primary osteosarcoma. Cancer Res. 2004;64:2047-2053.","journal-title":"Cancer Res"},{"key":"27_CR37_27","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3928\/0147-7447-20050801-11","volume":"28","author":"ST Jung","year":"2005","unstructured":"Jung ST, Moon ES, Seo HY, Kim JS, Kim GJ, Kim YK. Expression and significance of TGF-beta isoform and VEGF in osteosarcoma. Orthopedics. 2005;28:755-760.","journal-title":"Orthopedics"},{"key":"27_CR38_27","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/ijc.22749","volume":"121","author":"R Yang","year":"2007","unstructured":"Yang R, Hoang BH, Kubo T, et al. Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma. Int J Cancer. 2007;121:943-954.","journal-title":"Int J Cancer"},{"issue":"10","key":"27_CR39_27","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1002\/cncr.23437","volume":"112","author":"T Kubo","year":"2008","unstructured":"Kubo T, Piperdi S, Rosenblum J, et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer. 2008;112(10):2119-2129.","journal-title":"Cancer"},{"key":"27_CR40_27","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1056\/NEJM199511233332103","volume":"333","author":"N Baldini","year":"1995","unstructured":"Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of p-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med. 1995;333:380-1385.","journal-title":"N Engl J Med"},{"key":"27_CR41_27","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1200\/JCO.2006.07.7776","volume":"25","author":"CL Schwartz","year":"2007","unstructured":"Schwartz CL, Gorlick R, Teot L, et al. Multiple Drug Resistance in Osteogenic Sarcoma (INT0133). J Clin Oncol. 2007;25:2057-2062.","journal-title":"J Clin Oncol"},{"key":"27_CR42_27","first-page":"621","volume":"5","author":"W Guo","year":"1999","unstructured":"Guo W, Healey JH, Meyers PA, et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res. 1999;5:621-627.","journal-title":"Clin Cancer Res"},{"key":"27_CR43_27","first-page":"837","volume":"9","author":"R Yang","year":"2003","unstructured":"Yang R, Sowers R, Mazza B, et al. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin Cancer Res. 2003;9:837-844.","journal-title":"Clin Cancer Res"},{"key":"27_CR44_27","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1158\/0008-5472.CAN-04-2463","volume":"65","author":"MB Mintz","year":"2005","unstructured":"Mintz MB, Sowers R, Brown KM, et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 2005;65:1748-1754.","journal-title":"Cancer Res"},{"key":"27_CR45_27","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/pbc.21078","volume":"49","author":"PJ Houghton","year":"2007","unstructured":"Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer. 2007;49:928-940.","journal-title":"Pediatr Blood Cancer"},{"key":"27_CR46_27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/0008-5472.CAN-06-0610","volume":"67","author":"CC Whiteford","year":"2007","unstructured":"Whiteford CC, Bilke S, Greer BT, et al. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res. 2007;67:32-40.","journal-title":"Cancer Res"},{"key":"27_CR47_27","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/pbc.21232","volume":"50","author":"JM Maris","year":"2008","unstructured":"Maris JM, Courtright J, Houghton PJ, et al. Initial Testing (Stage 1) of the VEGFR Inhibitor AZD2171 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2008;50:581-587.","journal-title":"Pediatr Blood Cancer"},{"key":"27_CR48_27","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/pbc.21263","volume":"50","author":"M Tajbakhsh","year":"2008","unstructured":"Tajbakhsh M, Houghton PJ, Morton CL, et al. Initial testing of cisplatin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:992-1000.","journal-title":"Pediatr Blood Cancer"},{"key":"27_CR49_27","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/pbc.21296","volume":"50","author":"PJ Houghton","year":"2008","unstructured":"Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:799-805.","journal-title":"Pediatr Blood Cancer"},{"key":"27_CR50_27","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1002\/pbc.21368","volume":"50","author":"EA Kolb","year":"2000","unstructured":"Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2000;50:1198-1206.","journal-title":"Pediatr Blood Cancer"},{"key":"27_CR51_27","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1002\/pbc.21433","volume":"50","author":"R Lock","year":"2008","unstructured":"Lock R, Carol H, Houghton PJ, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:1181-1189.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"27_CR52_27","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/pbc.21450","volume":"50","author":"EA Kolb","year":"2008","unstructured":"Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50(6):1190-1197.","journal-title":"Pediatr Blood Cancer"},{"key":"27_CR53_27","first-page":"710","volume":"710","author":"C Hernan","year":"2008","unstructured":"Hernan C, Morton CL, Houghton PJ, et al. Pediatric Preclinical Testing Program (PPTP) evaluation of the topoisopmerase I inhibitor topotecan. Proc AACR. 2008;710:710. [abstract].","journal-title":"Proc AACR"},{"key":"27_CR54_27","first-page":"710","volume":"49","author":"PJ Houghton","year":"2008","unstructured":"Houghton PJ, Morton CL, Maris JM, et al. Pediatric Preclinical Testing Program (PPTP) evaluation of the Aurora A kinase inhibitor MLN8237. Proc AACR. 2008;49:710. [abstract].","journal-title":"Proc AACR"},{"key":"27_CR55_27","first-page":"710","volume":"49","author":"MA Smith","year":"2008","unstructured":"Smith MA, Morton CL, Maris JM, et al. Pediatric Preclinical Testing Program (PPTP) evaluation of the MEK 1\/2 inhibitor AZD6244 (ARRY-142886). Proc AACR. 2008;49:710. [abstract].","journal-title":"Proc AACR"}],"container-title":["Cancer Treatment and Research","Pediatric and Adolescent Osteosarcoma"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4419-0284-9_27.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T22:38:21Z","timestamp":1605652701000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4419-0284-9_27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"ISBN":["9781441902832","9781441902849"],"references-count":55,"URL":"https:\/\/doi.org\/10.1007\/978-1-4419-0284-9_27","relation":{},"ISSN":["0927-3042"],"issn-type":[{"value":"0927-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2009]]}}}